BetterLife Pharma Targets $500K in Private Placement
Company Announcements

BetterLife Pharma Targets $500K in Private Placement

Betterlife Pharma Inc. (TSE:BETR) has released an update.

BetterLife Pharma Inc., a biotech company specializing in non-hallucinogenic LSD-based treatments for mental disorders, has announced plans for a Non-Brokered Private Placement aiming to raise $500,000. These funds are intended to advance the development of their leading drug candidate, BETR-001, and for general corporate purposes. The offering will include common shares and warrants, with the closing date to be announced following completion.

For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBetterLife Pharma Secures $1.1M for LSD-Based Therapy
TipRanks Canadian Auto-Generated NewsdeskBetterLife Pharma Unveils Non-Hallucinogenic Mental Health Treatment
GlobeNewswireBetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App